New hope for stomach cancer patients who failed standard treatments
Disease control
Not yet recruiting
This study tests a new drug called NB003 for people with advanced gastrointestinal stromal tumors (GIST) that have worsened after standard treatments. The trial has two parts: one compares NB003 to another drug (regorafenib) for patients who have already tried two prior therapies…
Phase: PHASE2, PHASE3 • Sponsor: Ningbo Newbay Technology Development Co., Ltd • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC